問卷

TPIDB > Study Site

Study Site



MacKay Memorial Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • mmhcto@gmail.com
  • Alice Huang
  • 25433535-2851
  • 104Taipei CityJhong ShanNo. 92, Sec. 2, Zhongshan N. Rd., Taipei City 10449, Taiwan

篩選

List

566Cases

2025-11-01 - 2030-06-07

Others

Active
A phase 3b/4, multicenter, randomized, open-label, long-term safety trial comparing deucravacitinib with ustekinumab in participants with moderate to severe plaque psoriasis (PRAGMATYK).
  • Condition/Disease

    Participants with moderate to severe plaque psoriasis (PRAGMATYK)

  • Test Drug

    Shu Ting Coated Tablets 6 mg

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2025-11-03 - 2027-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of OBI- 858 in Subjects with Moderate to Severe Glabellar Lines.
  • Condition/Disease

    Moderate to severe frown lines

  • Test Drug

    Freeze-dried injection

Participate Sites
8Sites

Recruiting8Sites

2025-12-27 - 2032-05-15

Phase III

Active
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)
  • Condition/Disease

    Endometrial Cancer

  • Test Drug

    Frozen crystal powder for injection Solution Infusion solution Infusion solution

Participate Sites
5Sites

Not yet recruiting3Sites

2025-12-28 - 2031-12-31

Phase III

Not yet recruiting
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (WHO Group 3)
  • Condition/Disease

    Pulmonary Hypertension Due to Lung Disease (Disorder)

  • Test Drug

    Inhalation suspensions

Participate Sites
5Sites

Recruiting5Sites

2025-11-19 - 2030-06-30

Phase II

Not yet recruiting
A phase 2 open-label trial of navicixizumab monotherapy in patients with platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
  • Condition/Disease

    Platinum-based therapy-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer

  • Test Drug

    Navicixizumab

Participate Sites
10Sites

Recruiting10Sites

2019-12-01 - 2030-05-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Not yet recruiting4Sites

Recruiting13Sites

2020-11-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2021-06-01 - 2031-12-24

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2023-01-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-05-01 - 2025-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites